Lakefront Completes Sale of CAR-T Pipeline to Armed Cell Therapeutics for €8M Upfront
LKFT is trading near its 52-week low of $25.68 (15% above the low).
Summary
Lakefront completed the sale of its preclinical CAR-T programs to Armed Cell Therapeutics for €8 million upfront, up to $230 million in milestones, and a low-single-digit royalty, substantially finishing its cell therapy wind-down.
Key Events · M&A and Partnerships · LKFT
-
CAR-T Pipeline Divested
Lakefront completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotech formed by Paul Stoffels, John Mellors and Peter Verhaeghe.
-
Deal Terms: €8M Upfront Plus Milestones
The agreement includes €8 million upfront, up to $230 million in potential milestone payments, and a low-single-digit royalty to Lakefront.
-
Cell Therapy Wind-Down Complete
The previously announced wind-down of legacy cell therapy activities is substantially complete, following a strategic alternatives review.
-
Focus Shifts to T-Cell Engagers
Lakefront retains its clinical-stage immunology and inflammation portfolio anchored by gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases.
Analysis · LKFT · Life Sciences
The divestiture of Lakefront's legacy preclinical CAR-T programs has closed, bringing in €8 million upfront, up to $230 million in contingent milestones, and a low-single-digit royalty. This completes the wind-down of the cell therapy unit announced earlier, allowing management to focus resources on the clinical-stage immunology pipeline anchored by gamgertamig. While the upfront cash is modest relative to the company's balance sheet, the milestone and royalty structure preserves optionality on the assets without further spending.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LKFT was trading at $29.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $25.68 to $36.24. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.